Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

New app-based trial aims to shrink waistlines in endometrial cancer survivors

NCT ID NCT06038032

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now This study
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This study tests whether a 24-week digital wellness platform, combined with one-on-one online sessions with a dietitian, exercise pro, and therapist, can help endometrial cancer survivors lose inches around their waist and improve their health. About 148 survivors who are overweight and finished cancer treatment will participate. The main goal is to see if waist circumference shrinks after 16 weeks.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
digital wellness platform with online support from a dietitian, exercise professional, and mental health therapist
What this could lead to
If it works, this could offer a practical, home-based program to help endometrial cancer survivors improve their waistline and overall health after treatment.
What could go wrong
This is a relatively small, early-stage trial (148 people) testing a behavioral intervention, not a drug. Results may not apply to all survivors, and sticking with the program for 24 weeks may be challenging.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Not a phased trial

Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.

Participants

About 148 people

The number the study aims to enrol. It can still change while the study runs.

Started

Mar 2024

Expected to finish

Mar 2028

An estimate. End dates often move.

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 years and older

Sex

Female participants only

Healthy volunteers

Accepted

You do not need to have the condition being studied to take part.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * ≥ 18 years old * Histologically confirmed endometrioid adenocarcinoma (low-grade), FIGO 2009 stages I to III. * 1 month to 10 years post-surgery and completion of adjuvant treatment. * BMI ≥25 and ≤45 kg/m2. * Willing and able to adhere to the study interventions and assessments * Seeking best weight using the readiness to change questionnaire. * Have a cell phone compatible with the Fitbit app with internet access and Bluetooth capabilities. * Able to speak, read and understand English. Exclusion Criteria: * Recurrent (local, regional, or distant) or metastatic EC. * Abnormal (i.e., mutated) p53 status in combination with FIGO 2009 stage III or IV * Weight fluctuations (±5 kg) within the previous 3 months. * Planned surgery in the next 6 months. * Previous bariatric surgery. * Uncontrolled thyroid disorder * Type 1 diabetes. * Type 2 diabetes with HbA1c \> 10% or are taking insulin, sulfonylureas, or GLP-1 agonists. * Taking corticosteroids. * Taking anti-obesity drugs. * Current smoker (of any type, e.g e-cigarettes, tobacco, marihuana, vaping) * Self-report \>90 moderate-intensity min/week of aerobic physical activity on average over the past three months. * Potential safety risk with exercise or maximal exercise testing screened with the 2023 Physical Activity Readiness Questionnaire (PAR-Q+)53, signs and symptoms of CVD, and any of the American Heart Association's absolute or relative contraindications to exercise testing. * Physical or mobility limitations impacting ability to perform physical activity. * Self-report following a structured hypocaloric diet (e.g., using formulated meal replacements, weight loss meal program) or a restrictive diet (intermittent fasting, or high-fat diet) in the past three months, or self-report currently following a vegan diet but for less than two years. * Self-reported history of an eating disorder diagnosed by a physician. * Intending to be away longer than 2 weeks consecutively during the intervention and unable to adhere to the study protocol during this period. * Active substance abuse (alcohol, cannabis, illicit drugs, prescription drugs). * Dual-energy x-ray absorptiometry (DXA) or magnetic resonance imaging (MRI) contraindications for research purposes, such as pacemakers or pregnancy * Unable to participate in telephone and virtual intervention protocols (e.g., having a severe hearing or vision loss). * Unable to adhere to the study protocol (i.e., unavailable to commit to scheduled group video conferencing sessions; limited access to the Internet; not willing to use platform, individuals who have been advised by a health professional not to lose weight or reduce caloric intake; cognitive impairment or dementia; etc.). * Unable to come to study location. * Unable to provide written informed consent.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Endometrial cancer are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

How to take part

Only the study team decides who joins. These are the ways to reach them.

  1. The places running it

    2 sites. The list below names each one and where it is.

  2. The official record

    ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.

    Open the record ↗

  3. A doctor treating you

    A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.

Contacts and locations

Locations

  • University of Alberta

    RECRUITING

    Edmonton, Alberta, T6G 2E1, Canada

  • University of Toronto

    RECRUITING

    Toronto, Canada

More trials for these conditions

Other studies related to the condition(s) this trial covers.